Approximately 20% of breast cancer cases are human epidermal growth factor receptor 2
(HER2)-positive. This type of breast cancer is more aggressive and tends to reoccur more …

Background Human epidermal growth factor receptor2 (Her2) positive breast cancer
represents 25% of breast cancer cases. Targeted therapy with Her2 monoclonal antibody …

Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor
receptor 2 (HER2), offers a promising strategy of anticancer drug targeting to HER2 …

Purpose Conjugation of nanocarriers with antibodies that bind to specific membrane
receptors that are overexpressed in cancer cells enables targeted delivery. In the present …

Background Antibody-dendrimer conjugates have the potential to improve the targeting and
release of chemotherapeutic drugs at the tumor site while reducing adverse side effects …

The strategy utilizing trastuzumab, a humanized monoclonal antibody against human
epidermal growth receptor 2 (HER-2), as a therapeutic agent in HER-2 positive breast …

Because of the synergistic effects of drugs and minimal drug dose for cancer therapy,
combination chemotherapy is frequently used in the clinic. In this study, hyaluronic acid …

Although many breast and lung cancers overexpress human epidermal growth factor
receptor-2 (HER-2), no methods currently exist for effective and early detection of HER-2 …

Peptide dendrimers have shown promise as an attractive platform for drug delivery. In this
study, mPEGylated peptide dendrimer–doxorubicin (dendrimer–DOX) conjugate‐based …

Background Targeted contrast nanoparticles for breast tumor imaging facilitates early
detection and improves treatment efficacy of breast cancer. This manuscript reports the …